AbbVie cuts Editas CRISPR pact it inherited from Allergan

AbbVie cuts Editas CRISPR pact it inherited from Allergan

Source: 
Fierce Biotech
snippet: 

Editas Medicine’s shares fell by nearly 4% afterhours when Allergan’s new owner AbbVie decided to end a deal originally penned under its buyout with the gene-editing biotech.

The pact between Editas and Allergan was penned back in the spring of 2017, with the biotech getting $90 million for a CRISPR research pact that focused on ocular disorders.